Daraxonrasib Pill Eradicates Tumors in Early Pancreatic Cancer Trial
The targeted therapy daraxonrasib, combined with standard chemotherapy, eliminated detectable tumors in 8 percent of patients with metastatic pancreatic cancer in a new clinical trial. The results offer a potential first-line alternative for a disease that has historically resisted treatment.
By Aylin Aksoy
Share this story
At the EORTC-NCI-AACR Symposium in Barcelona on November 19, 2026, researchers presented updated Phase 1/2 trial data for the targeted therapy daraxonrasib. When combined with standard chemotherapy, the daily pill shrank tumors in 60.7 percent of patients with previously untreated metastatic pancreatic adenocarcinoma.[1][5][6]
In 8.2 percent of the 61 patients treated in the cohort, the tumors vanished entirely. This complete response rate represents a rare outcome in a disease that has historically resisted both targeted therapies and immunotherapies. The median progression-free survival reached 12.8 months.[1][6]
"By combining daraxonrasib with chemotherapy, we are seeing remarkably deep tumour responses in a substantial proportion of patients," said Dr. W. Park, the principal investigator. He noted that the regimen provided durable disease control that outpaces the historical expectations for conventional chemotherapy.[5]
Pancreatic cancer remains one of the most lethal malignancies, largely because it is typically diagnosed after it has spread. For patients with metastatic disease, the five-year relative survival rate hovers around 3 percent globally. Most patients treated with standard chemotherapy survive for eight to eleven months.[5][6]
The new data suggests a potential shift in that prognosis. After a median follow-up of 18.3 months, the 12-month overall survival rate for the combination therapy stood at 76.6 percent. The overall disease control rate—meaning tumors either shrank or stopped growing—reached 90.2 percent.[6]
Targeting the RAS Mutation
The mechanism behind daraxonrasib represents a breakthrough in molecular biology. More than 90 percent of pancreatic ductal adenocarcinomas are driven by mutations in the RAS gene family. These genes act as molecular switches that regulate cell growth and division.[5][7]
In pancreatic cancer, the mutated RAS switch becomes permanently stuck in the "on" position, continuously sending signals that drive cancer cells to multiply. For decades, researchers considered the resulting KRAS protein "undruggable" because its smooth surface lacked obvious pockets where a drug could bind.[7]
Daraxonrasib overcomes this structural hurdle by acting as a molecular glue. The drug binds the active RAS protein to cyclophilin A, a protein that ordinarily does not interact with RAS. This tethering inactivates the oncogenic driver and suppresses the downstream signaling pathways.[7]
Unlike earlier RAS inhibitors that only target a single specific mutation, daraxonrasib is a multi-selective inhibitor. It can turn off the active protein regardless of which specific RAS variant has mutated, making it applicable to a much broader patient population.[7]
In the Phase 1/2 RMC-GI-102 trial, patients received 200 milligrams of daraxonrasib orally each day. This targeted approach was paired with intravenous gemcitabine and nab-paclitaxel, administered on days 1 and 15 of a 28-day treatment cycle.[5][6]
Expanding Regulatory Clearances
The Barcelona presentation follows a major regulatory milestone for the drug as a standalone second-line treatment. On November 16, 2026, the European Commission approved daraxonrasib monotherapy for adults with metastatic pancreatic cancer who have received at least one prior systemic therapy.[3]
The European clearance applies across all European Union member states, as well as Iceland, Norway, and Liechtenstein. The decision followed an expedited review under the European Medicines Agency's Cancer Medicines Pathfinder project, reflecting the high unmet medical need in pancreatic oncology.[3]
That approval was based on the Phase 3 RASolute 302 trial, which evaluated daraxonrasib against standard chemotherapy in 500 previously treated patients. The trial demonstrated a median overall survival of 13.2 months for the daraxonrasib group, compared to 6.7 months for the chemotherapy cohort.[3]
Progression-free survival in the RASolute 302 trial also doubled, reaching 7.2 months versus 3.6 months for standard care. The U.S. Food and Drug Administration had previously approved the drug under the brand name Rasonque on August 26, 2026, based on the same pivotal data.[3]
"For decades, physicians treating metastatic pancreatic cancer have had limited options beyond cytotoxic chemotherapy, underscoring the urgent need for new therapeutic approaches," said Dr. Thomas Seufferlein, a medical director at Ulm University Hospital. He called the European approval an important advance for patients.[3]
Managing the Safety Profile
While the efficacy data has generated optimism, researchers are closely monitoring the drug's safety profile. In the first-line combination trial, the adverse events were consistent with the known toxicities of both daraxonrasib and the chemotherapy agents gemcitabine and nab-paclitaxel.[6]
Common side effects of daraxonrasib include dermatologic toxicities, such as rash, and gastrointestinal issues like stomatitis, nausea, and diarrhea. When combined with chemotherapy, patients also experienced expected hematological side effects, including anemia and decreased neutrophil counts.[6]
Despite these toxicities, the combination regimen was generally well tolerated, with a mean dose intensity exceeding 80 percent for both the targeted therapy and the chemotherapy. Only a small percentage of patients had to permanently discontinue the treatment due to adverse events.[6]
The ability to maintain sufficient dose intensity is critical for sustaining the continuous suppression of RAS signaling. By keeping the cancer cells starved of their primary growth signal, the combination therapy leverages the additional antitumor contribution of the cytotoxic chemotherapy.[6]
Community oncologists are already adapting to the drug's unique management requirements. Following the U.S. approval in August 2026, cancer centers reported that administrative hurdles, rather than drug availability, were the primary barriers to initiating treatment promptly.[3]
Moving to First-Line Treatment
The durability of the responses seen in the Phase 1/2 data provides a compelling rationale for moving daraxonrasib to the front of the treatment sequence. The U.S. FDA recently granted Breakthrough Therapy Designation for the combination regimen in the first-line setting.[6]
Revolution Medicines is now enrolling patients in the global Phase 3 RASolute 303 trial. This three-arm study will evaluate daraxonrasib monotherapy and the combination of daraxonrasib plus chemotherapy, comparing both against a control arm of chemotherapy alone in treatment-naïve patients.[6]
Independent experts remain cautiously optimistic about the preliminary findings. Professor Shivan Sivakumar of the University of Birmingham noted that the 61-patient study lacked a randomized control group, meaning comparisons with historical chemotherapy results are not definitive.[2]
"What is particularly exciting is the potential to move beyond chemotherapy as the mainstay of treatment for pancreatic cancer," Sivakumar said. He emphasized that targeting a fundamental driver like RAS could usher in an era where molecular therapies meaningfully improve outcomes.[2]
"The ongoing international phase III RASolute 303 trial will be critical in determining whether this combination genuinely improves survival compared with standard chemotherapy," Sivakumar added. "If these findings are confirmed, this could represent one of the most significant advances in the first-line treatment of metastatic pancreatic cancer in recent years."[2]
"If these findings are confirmed, this could represent one of the most significant advances in the first-line treatment of metastatic pancreatic cancer in recent years."
Until those Phase 3 results mature, the early evidence of tumor eradication offers a tangible milestone. For a disease defined by its resistance to intervention, the ability to completely clear detectable tumors in a subset of patients marks a definitive shift in the therapeutic landscape.[4]
Key points
- Daraxonrasib combined with chemotherapy shrank tumors in 60.7 percent of patients with previously untreated metastatic pancreatic cancer.
- In 8.2 percent of treated patients, the tumors vanished entirely, achieving a complete response.
- The combination therapy extended median progression-free survival to 12.8 months, significantly outpacing historical chemotherapy outcomes.
- The European Commission recently approved daraxonrasib as a standalone second-line treatment, expanding its global regulatory footprint.
What we don’t know
- Whether the combination therapy will definitively improve overall survival compared to chemotherapy alone in a large, randomized Phase 3 trial.
- How long the complete responses will last for the 8.2 percent of patients whose tumors were eradicated.
- Which specific patient subgroups or biomarkers might predict the deepest and most durable responses to the combination regimen.
How we got here
August 2026
The U.S. FDA approves daraxonrasib monotherapy for previously treated metastatic pancreatic cancer.
September 2026
Researchers publish data showing daraxonrasib nearly doubles survival time compared to second-line chemotherapy.
November 16, 2026
The European Commission grants marketing authorization for daraxonrasib as a second-line treatment.
November 19, 2026
Phase 1/2 trial data presented in Barcelona shows the drug eradicates tumors in 8 percent of patients when combined with first-line chemotherapy.
- Clinical Researchers
- Focus on the molecular breakthrough of targeting the RAS pathway and the unprecedented response rates.
- Independent Oncologists
- Emphasize the need for randomized Phase 3 data to confirm long-term survival benefits over standard chemotherapy.
- Regulatory Authorities
- Prioritize rapid access to novel therapies for aggressive cancers with high unmet medical needs.
Perspectives this story doesn't cover
- Patients currently enrolled in the expanded access programs
- Health insurance providers evaluating coverage for the new combination regimen
Sources
[1]Bioengineer.orgClinical ResearchersDaraxonrasib Chemotherapy Combination Shows Promising Tumour Shrinkage in Metastatic Pancreatic Cancer Trial
Read on Bioengineer.org →
[2]Science Media CentreIndependent Oncologistsexpert reaction to abstract about Daraxonrasib plus GnP for metastatic pancreatic adenocarcinoma
Read on Science Media Centre →
[3]OncLiveRegulatory AuthoritiesDaraxonrasib Gains EC Approval in Previously Treated Metastatic Pancreatic Cancer
Read on OncLive →
[4]BBCRegulatory AuthoritiesMassive hope for pancreatic cancer pill after trial saw tumours vanish
Read on BBC →
[5]EurekAlert!Clinical ResearchersMetastatic pancreatic cancer responds well to initial treatment with combination of daraxonrasib and chemotherapy
Read on EurekAlert! →
[6]Revolution MedicinesClinical ResearchersRevolution Medicines Presents Updated Phase 1/2 Data for RASONQUE® (daraxonrasib) Plus Chemotherapy in First-Line Metastatic Pancreatic Cancer at ENA 2026
Read on Revolution Medicines →
[7]The BMJIndependent OncologistsWhat is daraxonrasib?
Read on The BMJ →
More in Health
See all →Oncology Trials
Tovecimig Combination Demonstrates Response and Progression Gains in Advanced Biliary Tract Cancer
4 sources
Cancer Immunotherapy
FDA Approves Jemperli Immunotherapy to Treat Rectal Cancer Without Surgery or Chemotherapy
7 sources
Receptor Mechanics
How Benzodiazepines Increase Chloride Ion Flux by Positive Allosteric Modulation of the GABA-A Receptor
9 sources
Lung Cancer
Novel Targeted Therapy Zidesamtinib Achieves 94% Response Rate in Pivotal Trial for ROS1-Positive Lung Cancer
5 sources
Comments
Every angle. Every day.
Get Health stories with full source coverage and perspective breakdowns, free every day.




